Señales en vivo de GTBP | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 may 2024 @ 16:00):

Stats
Volumen de hoy	17 132.00
Volumen promedio	1.37M
Capitalización de mercado	8.09M
EPS	$0 ( 2024-05-20 )
Próxima fecha de ganancias	( $-2.70 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.530
ATR14	$0.0430 (1.15%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Breen Michael Martin	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Sell	200 000	Common Stock
2023-06-16	Casamento Charles J	Buy	500 000	Option to purchase Common Stock

INSIDER POWER
83.14
Last 90 transactions
Buy: 52 855 774 \| Sell: 22 501 893

Volumen Correlación

Largo: 0.10 (neutral)

Corto: -0.66 (moderate negative)

Signal:(47.71) Neutral

GT Biopharma, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GT Biopharma, Inc. Correlación - Moneda/Commodity

0.33
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.35
( neutral )

-0.30
( neutral )

GT Biopharma, Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-5.64

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-5.64

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-19.30

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.06

Financial Reports:

No articles found.

GT Biopharma, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

GT Biopharma, Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.